SG11202011311YA - Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway - Google Patents

Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway

Info

Publication number
SG11202011311YA
SG11202011311YA SG11202011311YA SG11202011311YA SG11202011311YA SG 11202011311Y A SG11202011311Y A SG 11202011311YA SG 11202011311Y A SG11202011311Y A SG 11202011311YA SG 11202011311Y A SG11202011311Y A SG 11202011311YA SG 11202011311Y A SG11202011311Y A SG 11202011311YA
Authority
SG
Singapore
Prior art keywords
treatment
heat shock
diseases associated
shock protein
modified sugar
Prior art date
Application number
SG11202011311YA
Other languages
English (en)
Inventor
Xin Jiang
Melean Visnick
Christopher Bender
Gary Bolton
Bradley CAPRATHE
Chitase Lee
Original Assignee
Reata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Inc filed Critical Reata Pharmaceuticals Inc
Publication of SG11202011311YA publication Critical patent/SG11202011311YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/203Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04Carbocyclic radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/11Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups containing rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10Oxygen atoms
    • C07D309/12Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11202011311YA 2018-05-14 2019-05-14 Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway SG11202011311YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862671047P 2018-05-14 2018-05-14
PCT/US2019/032292 WO2019222269A1 (fr) 2018-05-14 2019-05-14 Biarylamides comportant des groupes sucre modifiés pour le traitement de maladies associées à la voie de la protéine de choc thermique

Publications (1)

Publication Number Publication Date
SG11202011311YA true SG11202011311YA (en) 2020-12-30

Family

ID=67002352

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011311YA SG11202011311YA (en) 2018-05-14 2019-05-14 Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway

Country Status (16)

Country Link
US (2) US11827664B2 (fr)
EP (1) EP3794009A1 (fr)
KR (1) KR20210021457A (fr)
CN (1) CN112513058A (fr)
AU (1) AU2019271126A1 (fr)
BR (1) BR112020023277A2 (fr)
CA (1) CA3100333A1 (fr)
CL (1) CL2020002957A1 (fr)
CO (1) CO2020015380A2 (fr)
EA (1) EA202092727A1 (fr)
IL (2) IL309891A (fr)
MX (1) MX2020012366A (fr)
PE (1) PE20211917A1 (fr)
PH (1) PH12020551941A1 (fr)
SG (1) SG11202011311YA (fr)
WO (1) WO2019222269A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA125163C2 (uk) 2018-05-14 2022-01-19 Гіліад Сайєнсіз, Інк. Інгібітори mcl-1
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
EP4065567A1 (fr) 2019-11-26 2022-10-05 Gilead Sciences, Inc. Procédés et intermédiaires pour la préparation d'inhibiteurs de mcl1
US20230138729A1 (en) * 2021-09-13 2023-05-04 Rubedo Life Sciences, Inc. Coumarin Derivatives of Sugar Analogs and Uses Thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06501465A (ja) 1990-09-07 1994-02-17 シェリング・コーポレーション 抗ウイルス化合物
FR2792320B1 (fr) 1999-04-19 2003-05-09 Hoechst Marion Roussel Inc Nouveaux amides aromatiques substitues par un ribose, leur procede de preparation et leur application comme medicaments
US7053060B2 (en) 2000-11-30 2006-05-30 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
US7208630B2 (en) 2004-10-27 2007-04-24 University Of Kansas Heat shock protein 90 inhibitors
US7608594B2 (en) 2004-11-03 2009-10-27 University Of Kansas Novobiocin analogues as anticancer agents
WO2010096650A1 (fr) 2009-02-20 2010-08-26 University Of Kansas Analogues de novobiocine comportant des groupes fonctionnels glucidiques modifiés
US7622451B2 (en) 2004-11-03 2009-11-24 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
US8212012B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues having modified sugar moieties
US8212011B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues
DE602006017566D1 (de) 2005-08-30 2010-11-25 Boehringer Ingelheim Pharma Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
US8044041B2 (en) 2006-11-15 2011-10-25 Forest Laboratories Holdings Limited Phthalazine derivatives as inhibitors of protein kinase
DE102007002715A1 (de) * 2007-01-18 2008-07-24 Merck Patent Gmbh Triazolderivat
RS52978B (en) 2007-03-20 2014-02-28 Curis, Inc. FUSIONED AMINO PIRIDIN AS HSP90 INHIBITORS
US7960353B2 (en) 2007-05-10 2011-06-14 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
WO2010014617A1 (fr) 2008-07-28 2010-02-04 University Of Kansas Schémas posologiques pour inhibiteurs des protéines de choc thermique 90
WO2011041593A1 (fr) 2009-09-30 2011-04-07 University Of Kansas Analogues de novobiocine et traitement d'une maladie polykystique des reins
EP2594554A4 (fr) 2010-07-13 2014-01-15 Dainippon Sumitomo Pharma Co Dérivé d'amide biarylique ou un sel pharmaceutiquement acceptable de celui-ci
CA2832099C (fr) 2011-04-05 2019-07-09 Sloan-Kettering Institute For Cancer Research Inhibiteurs de hsp90
US9056104B2 (en) 2011-05-20 2015-06-16 The University Of Kansas Dynamic inhibitors of heat shock protein 90
PL2812341T3 (pl) 2012-02-09 2020-03-31 The University Of Kansas Inhibitory C-końcowe HSP90
WO2014181359A1 (fr) 2013-05-09 2014-11-13 Council Of Scientific & Industrial Research Procédé pour la préparation d'un agent anticonvulsivant : le chlorhydrate de prégabaline
US10689344B2 (en) 2013-11-07 2020-06-23 University Of Kansas Biphenylamide derivative Hsp90 inhibitors
EP3068778A2 (fr) 2013-11-11 2016-09-21 The University of Kansas Inhibiteurs hsp90 à base de coumarine à substituants d'urée et d'éther
US9994556B2 (en) 2014-06-13 2018-06-12 University Of Kansas Triazole modified coumarin and biphenyl amide-based HSP90 inhibitors
US10590065B2 (en) * 2014-06-24 2020-03-17 University Of Kansas Biphenyl amides with modified ether groups as HSP90 inhibitors and HSP70 inducers

Also Published As

Publication number Publication date
PH12020551941A1 (en) 2021-08-16
BR112020023277A2 (pt) 2021-02-23
KR20210021457A (ko) 2021-02-26
IL278698B2 (en) 2024-06-01
MX2020012366A (es) 2021-02-09
US11827664B2 (en) 2023-11-28
CN112513058A (zh) 2021-03-16
CA3100333A1 (fr) 2019-11-21
IL278698B1 (en) 2024-02-01
EA202092727A1 (ru) 2021-04-20
AU2019271126A1 (en) 2020-12-10
IL309891A (en) 2024-03-01
CL2020002957A1 (es) 2021-04-16
US20240182507A1 (en) 2024-06-06
JP2021524439A (ja) 2021-09-13
PE20211917A1 (es) 2021-09-28
US20210261592A1 (en) 2021-08-26
EP3794009A1 (fr) 2021-03-24
CO2020015380A2 (es) 2020-12-21
WO2019222269A1 (fr) 2019-11-21
IL278698A (fr) 2021-01-31

Similar Documents

Publication Publication Date Title
SG11202011311YA (en) Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway
IL251326A0 (en) Improved therapeutic control of heterodimeric and single chain forms of interleukin-12
DK3673080T3 (da) Antisense-oligomerer til behandling af lidelser og sygdomme
HK1246712A1 (zh) 神經刺激治療疾病及病症
IL287823A (en) Anti-cd40l antibodies and methods for treating diseases or disorders related to cd40l
ZA201702214B (en) Methods of using interleukin-10 for treating diseases and disorders
EP3148569A4 (fr) Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants
IL270746A (en) Inducers of heat shock proteins and frontal disorders
ZA202101587B (en) Protein for treatment of inflammatory diseases
IL271837A (en) A new medical fusion protein with an enzyme and its uses
PL3500586T3 (pl) Sposób ciągły zmniejszania heterogeniczności białka terapeutycznego
IL270781A (en) Treatment of depressive disorders
EP3420111C0 (fr) Procédé de traitement thermique ciblé sur les zones d'une pièce
IL283901A (en) Process pharmacists and intermediaries
IL249485A0 (en) History of o-alkylbenzylideneguanidine and therapeutic use for the treatment of disorders associated with the accumulation of misfolded proteins
EP3258930A4 (fr) Oxabicycloheptanes et oxabicycloheptènes permettant de traiter des troubles dépressifs et de stress
SG11201705677WA (en) Pulsating electromagnetic and ultrasound therapy for stimulating targeted heat shock proteins and facilitating protein repair
EP3341012A4 (fr) Procédés d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles
HK1245671A1 (zh) 使用白細胞介素-10治療疾病和病症的方法
FR3044227B1 (fr) Derives aminophosphiniques pour la prevention et le traitement des douleurs oculaires
GB201805100D0 (en) Treatment of sarcopenic diseases
IL284411A (en) Targeted transport of drug molecules
EP3615561C0 (fr) Variantes de la bmp7 proteine humaine
HK1256714A1 (zh) 製備治療性蛋白質的方法
GB201904810D0 (en) The treatment of protein aggregation diseases